Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SURPASS-SWITCH-2: Tirzepatide Switching Study in T2D
NCT05706506Phase 4Completed
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2023
- Primary completion
- Oct 2023
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 4 trial of tirzepatide in type 2 diabetes mellitus (T2DM), sponsored by Eli Lilly and Company. Started Mar 2023; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05706506.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05706506.